InCube Labs Announces $10 Million Department of Defense (DoD) Subcontract

Company will Collaborate with The University of Pittsburgh to Develop an Implantable Device for Spinal Cord Injury Patients

SAN ANTONIO, May 24, 2016 /PRNewswire/ — InCube Labs, a multi-disciplinary life sciences R&D lab, today announced that it has been awarded a subcontract from the University of Pittsburgh to help develop an implantable neuromodulation therapy to restore bladder function for spinal cord injury (SCI) patients.

As part of a multi-year, potential $10 million U.S. Department of Defense contract awarded to the University of Pittsburgh, a primary goal of the subcontract is submission to the FDA for an Investigational Device Exemption (IDE). An IDE would allow with the launch of clinical trials to test the device’s safety and efficacy and move towards commercialization of the technology. Dr. Changfeng Tai, Associate Professor of Urology, University of Pittsburgh, is the principal investigator of the DoD project.

According to the National Spinal Cord Injury Statistical Center (NSCISC), more than 275,000 Americans live with spinal cord injury, with more than 12,000 new cases a year. The neuromodulation therapy being developed is expected to significantly improve, if not fully restore, normal bladder function in a subset of these patients.

“We are delighted to have the opportunity to work with Pitt to solve this incredibly important clinical problem,” said Mir Imran, Chairman & CEO, InCube Labs.

“A number of SCI patients are suffering every day with bladder dysfunction, and it is our goal to use our expertise to come up with a solution that dramatically improves the lives of these patients,” added Dr. Pratap Khanwilkar, InCube’s Vice President of Product Development.

About InCube Labs

Based in San Jose and San Antonio, InCube Labs is a multi-disciplinary life sciences R&D lab focused on developing breakthrough medical innovations. InCube is led by Mir Imran, a prolific medical inventor, entrepreneur and investor, who has founded more than 20 life sciences companies and holds more than 400 patents. Many of Imran’s innovations have resulted in new standards of care, including the first FDA-approved Automatic Implantable Cardioverter Defibrillator. For more information, please visit:

SOURCE InCube Labs

Exit mobile version